You are here

Share:

Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Primary tabs

View PDF
Summary
Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
NIH Reference Number
E-055-2011
Product Type
  • Therapeutics
  • Vaccines
Keywords
  • cancer vaccine, Brachyury, transcription factor, T-cells, immunotherapy
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.

Potential Commercial Applications
  • Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.
  • Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.
  • Vaccine component of a multi-modal cancer therapy
Competitive Advantages
  • Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.
  • Vaccine can eliminate cancer stem cells which are resistant to conventional therapies
  • Compatible with the clinically-proven TRICOM cancer vaccine platform
  • Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines
Inventor(s)

Jeffrey Schlom (NCI), Claudia Palena (NCI)

Development Stage
  • Pre-clinical (in vivo)
Publications

R.I. Fernando et al. [PMID: 20071775]

C. Palena et al. [PMID: 17438107]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/701,525, Filed 14 Sep 2012
  • U.S. Patent Filed: U.S. Patent Application Number 14/428,308, Filed 13 Mar 2015
  • Foreign Filed: European - Patent Application 13773456.2, Filed 14 Apr 2015
Therapeutic Area
  • Cancer/Neoplasm
  • Immune System and Inflammation
Updated
Tuesday, March 20, 2018